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Abstract
Background: The aim of this study was to evaluate the disease outcomes of patients treated with definitive and
adjuvant radiotherapy for squamous cell carcinomas of the nasal cavity and paranasal sinuses in a single institution.
Methods: Between 2007–2012 patients were retrospectively identified from electronic databases who had
undergone surgery and adjuvant radiotherapy or definitive radiotherapy for sinonasal squamous cell carcinomas
with curative intent.
Results: Fourty three patients with sinonasal squamous cell carcinoma were identified (22 nasal cavity, 21 paranasal
sinuses). 31/43 (72 %) had T3 or T4 disease; nodal stage was N0 in 38, N1 in 4, Na/b in 0 and N2c in 1 patient. Median
age was 67 years (range 41–86). 18 (42 %) received definitive and 25 (58 %) adjuvant radiotherapy. Radiotherapy was
delivered using either conventional radiotherapy (n = 39) or intensity modulated radiotherapy (n = 4). Elective neck
radiotherapy was delivered to two patients. Chemotherapy was delivered to 6/43 (14 %) of patients. Two-year local
control, regional control, distant metastases free survival, progression free survival, cause specific survival and overall
survival were 81 %, 90 %, 95 %, 71 %, 84 % and 80 % respectively. There was no significant difference in outcome
comparing patients who underwent surgery and adjuvant radiotherapy with patients receiving definitive radiotherapy
(2 year locoregional disease free survival 75 % and 70 % respectively, p = 0.98). Pooly differentiated tumours were
significantly associated with inferior disease outcomes. Local, regional, combined local and regional, and distant failure
occurred in 7 (16 %), 3 (7 %), 1 (2 %) and 2 (5 %) of patients; all 3 regional recurrences were in patients with nasal cavity
squamous cell carcinomas who had not undergone elective neck treatment.
Conclusions: Definitive or adjuvant radiotherapy provides an effective treatment for sinonasal malignancies. The main
pattern of failure remains local, suggesting the need for investigation of intensified local therapy. Whilst remaining
uncommon, the cases of regional failure mean that the merits of elective lymph node treatment should be considered
on an individual basis.
Introduction
Sinonasal malignancies are rare [1] and include a wide
range of histopathological cell types [2, 3]. The anatomical
structure of the sinuses allows asymptomatic growth until
local structures/organs are invaded; most patients there-
fore present with locally advanced disease [4]. Determin-
ing optimal management continues to be challenging
due to the rarity of the disease and proximity to multiple
critical structures including the optic nerves, chiasm, eyes
and brainstem. Management choices have largely been in-
formed by single institution retrospective series. Treat-
ment approaches have generally involved surgery followed
by adjuvant radiotherapy, or definitive radiotherapy for
patients for whom complete surgical excision is unlikely,
co-morbidity or patient preference [4, 5].
Controversies remain in the management of sinonasal
squamous cell carcinomas. Local failure is the major
pattern of relapse and has guided treatment approaches
[6]. However, there is variation in practice regarding
the necessity for elective treatment of a clinically/radio-
logically N0 neck [6, 7]. In addition, by contrast with
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more common cancers sites within the head and neck
region, there is not a strong evidence based for the role
of chemotherapy; this at least partly relates to the rarity
of the disease. The use of chemotherapy has been gen-
erally at clinician discretion in several series [2, 5, 8]
In this study, we report the disease outcomes and
patterns of failure for patients with sinonasal squamous
cell carcinomas treated with radiotherapy in the post-
operative or definitive setting.
Materials and methods
Study design
A retrospective study was performed using patient re-
cords, radiotherapy treatment plans and diagnostic im-
aging on 43 patients who had been treated with either
definitive or adjuvant radiotherapy between 2007–2012
for sinonasal squamous cell cancers. Patients were ex-
cluded if radiotherapy was delivered with palliative in-
tent. Patients were staged according to the American
Joint Committee on Cancer 7th Edition [9]. Clinical and
radiological staging was used for patients treated non-
surgically, whilst pathological staging was used for pa-
tients who had undergone surgery.
Treatment
Surgery
All patients underwent evaluation in a Head and Neck
multidisciplinary team to evaluate the feasibility/
appropriateness of surgical resection. The type of surgery
depended upon primary site, extent of disease, cosmetic
considerations and discretion of the surgical team; surgery
was always aimed at obtaining a gross total resection.
Radiotherapy
Three patients with a nasal vestibule cancer were treated
with a direct electron field. 39/43 (91 %) of patients
were treated with a 3D-conformal photon technique
and toward the end of the study period six patients
(12 %) were treated with intensity modulated radio-
thearapy (IMRT). Patients were immobilised with a
Perspex mask with a neutral neck position. A CT scan
with 2-5 mm slices was acquired. MRI co-registration
was not available during the study period. A mouthbite
was routinely used to minimise the radiation dose to
the lower part of the oral cavity. A compartmental ap-
proach to target volume delineation was adopted. For pa-
tients receiving definitive radiotherapy a gross tumour
volume (GTV) was outlined as primary tumour and clin-
ically and/or radiologically involved lymph nodes. A pri-
mary tumour clinical target volume (CTV) was created to
include at least GTV+ 10 mm and modified to include the
whole involved anatomical compartment or sinus ie. all in-
vaded or partly invaded sinuses, modified to anatomical
boundaries to exclude air and/or bone without evidence of
invasion. For patients who had undergone macroscopically
complete surgical resection of the tumour, the same com-
partmental approach was adopted to delineate the CTV
encompassing the resection cavity. Elective treatment of
the neck was not routinely performed for clinically node
negative disease; neck treatment was delivered for N+ neck
disease. Planning target volumes (PTV) were generated by
an auto-expansion of 4 mm to CTV structures.
Organs at risk routinely delineated on the planning
CT scan included: optic chiasm, brainstem, optic nerves,
spinal cord.
Radiotherapy was delivered five fractions per week.
The prescription dose was at the discretion of the treat-
ing clinician; standard adjuvant doses were 60-66Gy in
30–33 fractions and definitive doses included a hypo-
fractionated regimen of 55Gy in 20 fractions in the early
part of the study period, and conventionally fractionated
66-70Gy in 33–35 fractions in the latter part of the
study. Standard dose constraints during this study period
were: spinal cord <48Gy, optic nerves, brainstem and
chiasm <54y, lens as low as achievable.
The 3D-conformal technique was based on either a
three-field technique with a heavily weighted anterior
portal with two lateral wedged portals or an anterior
wedged pair technique depending upon the target vol-
ume. IMRT was delivered with a 5–7 angle step and
shoot IMRT technique.
All photon treatment was delivered with 6MV photons.
Treatment was planned to provide adequate coverage of
the target volumes according to ICRU-62 guidelines [10].
Chemotherapy
Chemotherapy was employed upon clinician discre-
tion, based upon tumour histology and high risk fea-
tures. Concurrent chemotherapy was with cisplatin
100 mg/m2 days 1 and 29. Induction chemotherapy
regimens included cisplatin 80 mg/m2 day 1 and 5-
fluorouracil (5FU) 800 mg/m2 days 2–5, three weekly.
Follow up schedule
Patients were seen at least once per week during radio-
therapy treatment. For patients receiving definitive radio-
therapy, response assessment imaging with CT and/or
MRI was routinely performed 3 months post-treatment.
Patients were followed up with physical examination every
6–8 weeks in the first year after treatment, every 3 months
for an additional 2 years, and every 6 monthly until dis-
charge at 5 years. Suspected recurrence was detected by
clinical examination and radiological examination and bi-
opsy if appropriate.
Statistical analysis
Statistical analysis was performed using SPSS version 16
(IBM, USA), STATA version 10 (Statacorp, USA), and
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Prism version 6 (Graphpad, USA). Survival and recur-
rence outcomes were calculated from the date of their
curative treatment (i.e. date of curative surgery, date of
first fraction of radiotherapy). The following endpoints
were used for assessment: local control rate, regional
control rate, locoregional disease free survival (LRDFS),
distant metastases free survival (DMFS), progression free
survival (PFS), cause specific survival (CSS) and overall
survival (OS). For comparison of surgery and adjuvant
radiotherapy versus definitive radiotherapy, univariate
log-rank survival analysis was performed for each out-
come and hazard ratios (HR) and 95 % confidence inter-
vals calculated.
Results
Fourty three patients with sinonasal squamous cell car-
cinomas were identified who had received definitive or
adjuvant radiotherapy. Patient and disease characteristics
are summarised in Table 1. Median follow up was 32
(range 4–102) months. Median age was 67 years (range
41–86). 35/52 (67 %) had T4a or T4b disease.
Treatment details are summarised in Table 2. 25/43
(58 %) of patients had undergone surgery, with a positive
resection margin (<1 mm) reported in 13/25 (52 %) and
close (<5 mm) margins in 5/25 (20 %). 36/43 (84 %) of
patients received radiotherapy via a 3D-conformal tech-
nique. Neck radiotherapy was delivered to 3 patients; in
one case neck radiotherapy followed neck dissections for
N+ disease and in two cases elective neck radiotherapy
was delivered to the ipsilateral neck along with treatment
of the primary site following surgery for T4N0 squamous
cell carcinomas of the maxillary sinus. Chemotherapy was
delivered to a total of 6/43 (14 %) of patients. Comparing
patients who underwent surgery and adjuvant radiother-
apy and patients who received definitive radiotherapy,
there were significantly more patients undergoing surgery
with T4a disease (p < 0.001) and a non-significant trend
for more patients with maxillary tumours to undergo
surgery (p = 0.06). 12/18(67 %) patients who received
Table 1 Patient and tumour characteristics
Characteristics Number (n = 43) Percent
Gender
Male 25 60
Female 18 40
Tobacco use at diagnosis
Ex smoker 8 19
Current smoker 15 35
No smoker 7 16
Not documented 13 30
Tumour localisation
Maxillary sinus 20 47
Ethmoid sinus 1 2
Nasal cavity 22 51
Nasal vestibule 10 23
Nasal septum 3 7
Floor and lateral wall 9 21
T stage
T0 0 0
T1 6 14
T2 6 14
T3 2 5
T4a 23 53
T4b 6 14
N stage
N0 38 88
N1 4 9
N2a 0 0
N2b 0 0
N2c 1 3
Stage group (AJCC 2010)
I 6 14
II 6 14
III 2 5
IVa 23 53
IVb 6 14
Histopathology
SCC 43 100
Histopathological differentiation
Well differentiated 7 16
Moderately differentiated 18 40
Poorly differentiated 10 23
Undifferentiated 3 7
Not documented 6 14
Table 1 Patient and tumour characteristics (Continued)
Nodal involvement
Yes 3 7
No 40 93
Nodal ECE
Yes 1 20
No 4 80
Tumor invasion
Cranial 2 5
Orbital 2 5
Skin 7 16
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definitive radiotherapy were documented as having
achieved a complete clinical and radiological response
to treatment.
The 2-year local control rate, regional control rate,
DMFS, PFS, CSS and OS were 81 %, 90 %, 95 %, 71 %,
84 %, and 80 % respectively. 5-year local control rate, re-
gional control rate, DMFS, PFS, CSS and OS were 76 %,
90 %, 95 %, 66 %, 74 %, and 71 % respectively. Locore-
gional control, PFS and OS are illustrated in Fig. 1.
Local, regional, combined local and regional, and distant
failure occurred in 7 (16 %), 3 (7 %), 1 (2 %) and 2 (5 %)
of patients. Median time to local recurrence was not
reached. There was no significant difference compar-
ing outcomes of patients who underwent radical
radiotherapy (n = 18) and surgery and adjuvant radio-
therapy (n = 25): 2-year LRDFS was 70 % versus 75 %
(non-significant, p = 0.98), and 2-year CSS was 94 %
versus 79 % (non-significant, p = 0.6)). Recurrence pat-
terns are summarised in Table 3. Poorly differentiated
tumours were significantly associated with increased
risk of developing distant metastases (HR 8.2 (95 %
CI1.01-66) P = 0.05 and inferior CSS (HR2.31(95 %
CI1.06-5.0, P = 0.04). A total of eight patients experi-
enced local disease recurrence; one of these cases was
in combination with regional failure. Primary tumour
site involved nasal cavity in 4, ethmoid sinus in 1 and
maxillary sinus in 3 patients respectively; disease
stages were T4N0 in 6 patients, T1N0 in one patient
and T2N0 in one patient. Four of these patients had
initially undergone surgery and adjuvant radiotherapy
and four patients were initially treated with definitive
radiotherapy (one with concurrent chemotherapy).
The two patients with early stage disease at outset
underwent successful surgical salvage of local recur-
rence; the remaining six patients were managed with
palliative approaches.
The four patients who experienced a regional lymph
node recurrence had all undergone surgery and adju-
vant radiotherapy without elective neck surgery or ir-
radiation for squamous cell carcinoma of the nasal
cavity; one was a pT2 and the remaining cases pT4 dis-
ease. In these four cases one recurrence occurred with
simultaneous local recurrence. The pattern of regional
recurrences were in level II lymph nodes in one case,
level Ib lymph nodes in two cases and facial lymph
nodes in one case. Two patients with regional lymph
node recurrence underwent salvage surgery and radio-
therapy; one of these patients subsequently developed
widespread distant metastases whilst the other remains
disease free. One patient was not deemed fit for further
treatment, and one patient with synchronous local and
regional progression received palliative chemotherapy.
There were no cases of regional recurrences in patients
treated for paranasal sinus cancers.
Table 2 Treatment details
Number (n) (n = 43 unless
stated otherwise)
Percentage (%)
Surgery n = 25 58
Open 23 92
Endoscopy 2 8
Unilateral neck dissection 12 48
Bilateral neck dissection 2 8
Margin status n = 25
Positive 13 52
Close (<5 mm) 5 20
Negative (≥5 mm) 6 24
Unknown 1 4
Perineural invasion n = 25
Yes 5 20
No 10 40
Not reported 10 40
Lymphovascular invasion n = 25
Yes 1 4
No 13 52
Not reported 11 44
Radiotherapy
Electron 3 7
3DCRT 36 84
IMRT 4 9
Radiotherapy
Adjuvant 25 58
Radical 18 42
Radiotherapy dose
Radical
70 Gy/35 fx 5 12
68 Gy/34 fx 1 2
66 Gy/33 fx 2 5
55 Gy/20 fx 10 23
Adjuvant
66 Gy/33 fx 8 19
64 Gy/32 fx 3 7
62 Gy/31 fx 1 2
60Gy/ 30 fx 7 16
55 Gy/20 fx 6 14
Radiotherapy region
Primary 40 93
Primary and ipsilateral neck 3 7
Primary and bilateral neck 0 0
Chemotherapy
Induction 3 7
Concurrent 3 7
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Discussion
Sinonasal squamous cell carcinomas present a major
therapeutic challenge. In the absence of randomised tri-
als, treatment options for sinonasal malignancies are
based on retrospective series by institutions; due to the
rarity of the disease, data remains limited. Historical out-
comes following 2-dimensional radiotherapy are limited
in terms of disease outcomes and treatment-related late
morbidity [11–13]. The introduction of 3D-conformal
radiotherapy facilitated an improvement in disease and
toxicity outcomes [14–16]. More recently the advent of
IMRT techniques has allowed improved target volume
coverage with a minimisation of OAR doses [17]. Re-
ported outcomes in previous studies vary widely; for ex-
ample, local control rates and overall survival rates are
reported between 21–84 % and 9–89 % at 2 to 5 years
follow up [2]. Overall outcomes appear to be superior in
more recent series. For example, IMRT series have re-
ported 2-year local control rates of 62–76 % [2–5]; 2-
year overall survival in these modern series ranged from
66–89 %. Comparison between series is difficult, due the
heterogeneity of tumour site, stage, treatment approaches
and duration of follow up. In common with other
series, our report includes a both a mixture of primary
tumour sites including both nasal cavity and paranasal
sinuses [2–5, 8, 18]. Broadly, disease outcomes from
our series appear favourable compared with many series
and similar to those reported recently by other major in-
stitutions [2–4]. The proportion of patients in our series
with nasal cavity tumours was high (51 %) compared
with other reports (6–28 %, [2–5, 8, 18]). Although
there was no significant difference in outcomes between
nasal cavity and non-nasal cavity primary sites, this may
have influenced outcomes favourably in our predomin-
antly non-IMRT experience due to the comparative ease
by which nasal cavity tumours can be treated compared
with other paranasal sinus primaries with 3D-conformal
radiotherapy.
The conformality provided by IMRT appears to pro-
vide increased levels of local control with very low rates
of late toxicity [3–5, 8]. Recent series reporting out-
comes following IMRT for paranasal sinus malignancies
have reported no cases of optic neuropathy with limited
follow up [8, 19]. IMRT is now regarded as a standard
of care for paranasal sinus cancers [19]. A limitation of
our series is that the majority of patients were treated
with a 3D-conformal radiotherapy technique; IMRT is
now the standard of care within our institution for parana-
sal sinus tumours.
Patients with a gross tumour resection prior to
radiotherapy are associated with favourable outcomes
[18, 20, 21]. En bloc removal of macroscopic disease is
regarded as the aim of initial treatment. This has been
facilitated by ongoing improvements in surgical tech-
niques. There was no significant difference in outcome
in patients undergoing definitive radiotherapy and sur-
gery and adjuvant radiotherapy in our series. Although
hypothesis generating, these data may be influenced
by an imbalance between the groups with an excess of
nasal cavity cancers treated non-surgically.
The majority of failures in our series were local recur-
rences; this is consistent with multiple previous series
[2, 3, 8]. This suggests that the focus of improving
Fig. 1 Kaplan Meier curves showing a locoregional control, b progression free survival and c overall survival
Table 3 Patterns of disease recurrence
Recurrence site Number
Local
Radical 4
Adjuvant 3
Regional
Radical 0
Adjuvant 3
Local and regional
Radical 0
Adjuvant 1
Distant metastasis
Radical 1
Adjuvant 1
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sinonasal tumour outcomes will continue to be improv-
ing local treatment outcomes. The excellent results of
recent IMRT series suggest that the improved dose con-
formality leading to less compromise of target coverage
may translate into improved local control. Another
potential route to improving the efficacy of treatment is
the incorporation of chemotherapy. The role of chemo-
therapy in the treatment of sinonasal malignancies is
uncertain. Only 14 % of patients in our series received
either induction or concurrent chemotherapy at the dis-
cretion of the treating clinician. Similarly in some [2, 22]
but not all series [3–5], a limited proportion of patients
were treated with chemotherapy. An extrapolation from
other head and neck cancer sites [23] would suggest
that the use of concurrent chemotherapy may be advan-
tageous for squamous cell cancers. Although the delivery
of chemotherapy appears feasible as part of treatment for
sinonasal malignancies, current reported experiences are
unable to provide direct comparative evidence of efficacy.
The use of chemotherapy remains unproven for other
types of histological diagnosis [24].
Lymph node involvement in sinonasal malignancies
is less common compared with several other head and
neck tumour sites. However, involvement of lymph nodes
at presentation is recognised as a poor prognostic factor
for regional and distant disease [8, 24, 25], and patients
who relapse in regional lymph nodes have an adverse
prognosis [8]. In this series only two patient received
elective neck irradiation, both for T4N0 squamous cell
carcinomas of the maxillary sinus. Four patients devel-
oped regional recurrences on follow up; all of these
patients had primary cancers of the nasal cavity. The
average incidence of neck recurrences in untreated necks
following treatment of squamous cell carcinoma of the
maxillary sinus is 15 % [6]. The role of elective neck irradi-
ation remains controversial for sinonasal squamous cell
carcinomas [3, 6]. The National Comprehensive Cancer
Network guidelines recommend elective neck irradiation
for T3/T4 squamous cell maxillary carcinomas [26]. A
recent meta-analysis has suggested that elective neck ir-
radiation can reduce the rate of nodal recurrence for
patients with N0 squamous cell carcinoma of the maxil-
lary sinus [6]. The occurrence of regional nodal recurrence
following treatment of nasal cavity cancers suggest that
elective nodal radiotherapy could be considered for
patients with locally advanced squamous cell carcinoma of
the nasal cavity. Factors which need to be considered in
evaluating the need for elective neck irradiation for
patients on an individual basis include the histological
type of malignancy, site, local extent, pattern of potential
lymphatic spread and comorbidity.
Distant metastatic failure occurred in 2/43 (5 %) pa-
tients; other series including mixed histological diagnoses
have reported distant metastases occurring in 18–29 % of
patients [2, 4, 8]. These data suggest that although obtain-
ing local control remains a major issue, the potential for
distant disease dissemination needs to be considered in
designing novel approaches to improve the outcomes of
sinonasal malignancies.
One limitation of this series is the absence of robust
long term toxicity data. Treatment-related visual impair-
ment may occur with longer term follow up [27]. Tox-
icity is recorded in an ad-hoc manner without any
ophthalmological testing, and as such we are not able to
document toxicity in a reliable manner. Importantly,
IMRT techniques are now an established method to
minimise the risk of optic pathway complications from
radiotherapy treatment.
Conclusions
In summary, definitive or adjuvant radiotherapy provides
an effective treatment for sinonasal squamous cell carcin-
omas. The main pattern of failure remains local, suggest-
ing the need for investigation of intensified local therapy.
Whilst remaining uncommon, the cases of regional failure
mean that the merits of elective lymph node treatment
should be considered on an individual basis.
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